Revenue Insights: Jazz Pharmaceuticals plc and ACADIA Pharmaceuticals Inc. Performance Compared

Pharma Giants' Revenue Growth: Jazz vs. ACADIA

__timestampACADIA Pharmaceuticals Inc.Jazz Pharmaceuticals plc
Wednesday, January 1, 20141200001172875000
Thursday, January 1, 2015610001324803000
Friday, January 1, 2016173310001487973000
Sunday, January 1, 20171249010001618693000
Monday, January 1, 20182238070001890922000
Tuesday, January 1, 20193390760002161761000
Wednesday, January 1, 20204417550002363567000
Friday, January 1, 20214841450003094238000
Saturday, January 1, 20225172350003659374000
Sunday, January 1, 20237264370003834204000
Loading chart...

Unleashing insights

Revenue Growth: A Tale of Two Pharmaceutical Giants

In the competitive landscape of pharmaceuticals, Jazz Pharmaceuticals plc and ACADIA Pharmaceuticals Inc. have showcased distinct revenue trajectories over the past decade. Since 2014, Jazz Pharmaceuticals has consistently outperformed ACADIA, with its revenue growing by over 227% from 2014 to 2023. In contrast, ACADIA Pharmaceuticals, starting from a modest base, has seen a staggering increase of over 6,000% in the same period, reflecting its aggressive growth strategy.

By 2023, Jazz Pharmaceuticals reached a revenue peak of approximately $3.8 billion, while ACADIA's revenue surged to around $726 million. This growth narrative highlights Jazz's steady expansion and ACADIA's rapid ascent in the pharmaceutical sector. As these companies continue to innovate and expand, their financial performances offer valuable insights into the evolving dynamics of the industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025